Hospital Acquired Infections Treatment Market Size, Share and Global Trend By Infection Type (Bloodstream Infections, Ventilator-Associated Pneumonia (VAP), Urinary Tract Infection, Surgical-Site Infection, Gastrointestinal Infections), By Treatment (Antibacterial, Antiviral, Antifungal), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies) and Regional Forecast, 2024-2032

A hospital-acquired infection, also known as a nosocomial infection, is an infection that is acquired in a hospital or nursing home, outpatient clinics, rehabilitation facilities, or other clinical settings. Infection is spread to the susceptible patient in the clinical setting by various means. The infection can originate from another infected patient, staff, or external environment factors. In many cases, opportunistic microorganisms originated from surgery or any other medical procedures could give rise to nosocomial infections.

According to the World Health Organization (WHO), it is estimated that of among 100 hospitalized patients, 7 in developed nations and 10 patients in developing nations will develop at least one hospital-acquired infections every year. Growing investments in research activities by many key players in developing innovative treatment options to curb hospital-borne infections are likely to fuel hospital-acquired infections treatment market growth during the forecast period.

Increase in the prevalence of hospital-acquired infections, growing hospital admissions, and the presence of various pathogens causing infections in healthcare facility centers are anticipated to drive the global hospital-acquired infections treatment market growth during the forecast period.

Along with this rising awareness by many government organizations & key players to educate people about the emerging infections acquired during hospital admission & symptoms associated with it and the available treatment options are likely to propel the hospital-acquired infections treatment market growth during the forecast period.

However, poor healthcare infrastructures and lack of educational training in infection control in low-middle income countries are likely to hinder the hospital-acquired infections treatment market growth during the forecast period.

Key Players Covered

Some of the major companies that are present in the global hospital-acquired infections treatment market report include Abbott, AstraZeneca, Bayer AG, Pfizer Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer, Inc., Cipla Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, and F. Hoffmann-La Roche Ltd., among others

SEGMENTATION

In terms of infection type, urinary tract infection segment is anticipated to hold the largest share in the global hospital-acquired infections treatment market during the forecast period owing to the increase in the occurrence of catheter-associated urinary tract infections globally. For instance, according to the report published in 2019 by the Centers for Disease Control and Prevention (CDC) an estimated 12%-16% of adult inpatients undergo an indwelling urinary catheter (IUC) every year among which 3%-7% of patients are likely to develop the risk of infections due to catheter insertion and which is expected to drive the demand for medications for hospital-acquired infections.

Key Insights

• Overview of novel medications for the treatment of hospital-acquired infections


• Overview of pipeline drugs


• The Regulatory scenario for key countries/Regions


• Key Industry Developments-Mergers, Acquisitions, Partnerships, and New Product Launches, etc.

Regional Analysis

Geographically, the global hospital-acquired infections treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is likely to dominate the global hospital-acquired infections treatment market during the projected period owing to growing investments by many key players in research sectors to launch new treatment options. In Europe, rising awareness about hospital-acquired infections and the presence of many key players are likely to fuel the hospital-acquired infections treatment market growth. The Asia Pacific is anticipated to register significant CAGR in hospital-acquired infections treatment market owing to the growing patient population and improving healthcare infrastructure. In the Middle East & Africa, growing demand for cost-effective options for the treatment and growing prevalence of various chronic disease supported by large hospital admissions of patients are anticipated to boost the hospital-acquired infections treatment market growth during the forecast period.

Hospital Acquired Infections Treatment Industry Developments

• In June 2019, Merck & Co., Inc. received FDA approval for the use of antibiotic ZERBAXA for the treatment of patients 18 years and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).
• In October 2018, Paratek Pharmaceuticals, received FDA approval to use NUZYRA (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI).
• In February 2018, Allergan received FDA approval to use Avycaz for the treatment of nosocomial pneumonia in patients aged 18 years or older.